Annexure 3. Application Form for Expedited Review

Title of study:

Principal Investigator (Name, Designation and Affiliation):

Choose reasons why expedited review from EC is requested*?

i. Involve non-identifiable specimen and human tissue from sources like blood banks, tissue banks and left-over clinical samples ☐
ii. Involve clinical documentation materials that are non-identifiable (data, documents, records). ☐
iii. Modification or amendment to approved protocol (administrative changes/correction of typographical errors and change in researcher(s) ☐
iv. Revised proposals previously approved through expedited review, full review, or continuing review of approved proposals ☐
v. Minor deviations from originally approved research causing no risk or minimal risk ☐
vi. Progress/annual reports where there is no additional risk, for example activity limited to data analysis. Expedited review of SAEs/unexpected AEs will be conducted by SAE subcommittee. ☐
vii. For multicentre research where a designated EC has approved the proposal, a participating EC may review participating centre specific information and modification in the study proposal through full committee meeting/ expedited review depending on the importance of local consent related issues involved specific to the centre. ☐
viii. Research during emergencies and disasters (See Section 12 of ICMR Ethical Guidelines, 2017). ☐
ix. Any other (please specify) ☐

1. Is waiver of consent being requested ? Yes ☐ No ☐
2. Does the research involve vulnerable person*? Yes ☐ No ☐
   If yes, give details:

Signature of PI: Click here to enter a date.

**Refer to Table 2 as above and for more details National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2*